

## Davidson, Mark

---

**From:** Davidson, Mark  
**Sent:** Wednesday, May 17, 2017 1:09 PM  
**To:** Rizwana Sproule (RSproule@KitePharma.com)  
**Cc:** 'Alex Babayan'; Nadia Agopyan (NAgopyan@KitePharma.com)  
**Subject:** Kite Pharma BLA 125643 Clinical Information Request May 17, 2017  
**Attachments:** KITE BLA 125643 IRs 5-17-17.docx

**Importance:** High

Please see the attached request for ZUMA1 data. **Please respond by May 22, 2017.**

Please acknowledge receipt of this request!

Thank You

Mark L. Davidson, RHIA  
Regulatory Project Manager  
OTAT/CBER/FDA  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002  
Phone: 240-402-8277  
Fax:301-595-1303  
[mark.davidson@fda.hhs.gov](mailto:mark.davidson@fda.hhs.gov)

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."